|
Volumn 44, Issue 3, 2012, Pages 694-700
|
Cytomegalovirus disease in kidney transplant recipients: Incidence, clinical profile, and risk factors
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALEMTUZUMAB;
AZATHIOPRINE;
BASILIXIMAB;
CYCLOSPORIN A;
CYTOMEGALOVIRUS ANTIGEN;
DACLIZUMAB;
EVEROLIMUS;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
PREDNISONE;
RAPAMYCIN;
TACROLIMUS;
THYMOCYTE ANTIBODY;
UNCLASSIFIED DRUG;
VALGANCICLOVIR;
VIRUS ANTIGEN;
ADULT;
ANTIBODY TITER;
ANTIGEN DETECTION;
ARTICLE;
CLINICAL EXAMINATION;
CLINICAL FEATURE;
CYTOMEGALOVIRUS INFECTION;
FEMALE;
GRAFT RECIPIENT;
HOSPITALIZATION;
HUMAN;
INFECTION PREVENTION;
INFECTION RISK;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
MAJOR CLINICAL STUDY;
MALE;
MIXED INFECTION;
MORBIDITY;
PREOPERATIVE PERIOD;
PRIORITY JOURNAL;
PROPHYLAXIS;
TREATMENT OUTCOME;
ADOLESCENT;
ADULT;
AGED;
COHORT STUDIES;
CYTOMEGALOVIRUS INFECTIONS;
FEMALE;
HOSPITALIZATION;
HUMANS;
INCIDENCE;
KIDNEY TRANSPLANTATION;
LENGTH OF STAY;
MALE;
MIDDLE AGED;
RISK FACTORS;
YOUNG ADULT;
|
EID: 84859485906
PISSN: 00411345
EISSN: 18732623
Source Type: Journal
DOI: 10.1016/j.transproceed.2011.11.053 Document Type: Article |
Times cited : (55)
|
References (13)
|